9744
P. Sawant, M.E. Maier / Tetrahedron 66 (2010) 9738e9744
3.70e3.82 (m, 1H, dioxane CH), 3.85e3.94 (m, 1H, NCH2),
4.03e4.12 (m, 1H, NCH2), 4.16e4.26 (m, 1H, dioxane CH),
7.00e7.36 (m, 14H, aryl); dC (100 MHz, CD3OD) 20.0 (C(CH3)2),
22.6 (CH(CH3)2), 22.8 (CH(CH3)2), 27.6 (CH(CH3)2), 30.3 (C(CH3)2),
37.1 (CH2), 39.4 (dioxane CH2), 41.4 (CH2CO2H), 42.2 (NCH2), 67.2
(dioxane CH), 67.7 (dioxane CH), 100.0 (C(CH3)2), 116.3 (C-3,
JC,F¼22.0 Hz, 4-FeC6H4), 118.1 (C, aryl), 121.5 (CH, aryl), 123.3 (C,
aryl), 125.1 (CH, aryl), 126.9, 128.8, 128.9 (CH, aryl), 129.0, 129.5,
129.6 (CH, aryl), 129.6 (C, aryl), 130.2 (C-1, JC,F¼3.7 Hz, 4-FeC6H4),
130.9 (2 CH, aryl), 131.8, 132.8 (CH, aryl), 134.8 (2 C-2,
JC,F¼8.05 Hz, 4-FeC6H4), 136.3 (C, aryl), 139.0 (C, aryl), 139.8 (C,
aryl), 163.8 (C-4, JC,F¼246.6 Hz, 4-FeC6H4), 169.5 (CONH), 174.6
(COO); HRMS (ESI) calcd for C36H39FN2O5 [MþNa]þ 621.27352,
found 621.27359.
files and InChIKeys of the most important compounds described in
this article.
References and notes
1. For a review, see: Tobert, J. A. Nat. Rev. Drug Discovery 2003, 2, 517e526.
2. (a) Schachter, M. Br. J. Diabetes Vasc. Dis. 2003, 3, 178e182; (b) Davignon, J.
Circulation 2004, 109, III/39eIII/43.
3. (a) Martin-Ventura, J. L.; Blanco-Colio, L. M.; Gomez-Hernandez, A.; Munoz-
Garcia, B.; Vega, M.; Serrano, J.; Ortega, L.; Hernandez, G.; Tunon, J.; Egido, J.
Stroke 2005, 36, 1796e1800; (b) Torrens, C.; Kelsall, C. J.; Hopkins, L. A.; An-
thony, F. W.; Curzen, N. P.; Hanson, M. A. Hypertension 2009, 53, 661e667, and
references therein.
4. Weitz-Schmidt, G.; Welzenbach, K.; Brinkmann, V.; Kamata, T.; Kallen, J.; Bruns,
C.; Cottens, S.; Takada, Y.; Hommel, U. Nat. Med. 2001, 7, 687e692.
€
5. Laufer, S. University of Tubingen, Pharmaceutical Chemistry, Personal Com-
munication.
4.16. 5-(4-Fluoro-phenyl)-1-[2-(4-hydroxy-6-oxo-tetrahydro-
pyran-2-yl)-ethyl]-2-isopropyl-4-phenyl-1H-pyrrole-3-
carboxylic acid phenylamide (6)
6. Istvan, E. S.; Deisenhofer, J. Science 2001, 292, 1160e1164.
7. See, for example: Daub, H. Biochim. Biophys. Acta 2005, 1754, 183e190.
8. (a) Leslie, B. J.; Hergenrother, P. J. Chem. Soc. Rev. 2008, 37, 1347e1360; (b)
Sato, S.-i.; Murata, A.; Shirakawa, T.; Uesugi, M. Chem. Biol. 2010, 17,
616e623.
9. Roth, B. D.; Blankley, C. J.; Chucholowski, A. W.; Ferguson, E.; Hoefle, M. L.;
Ortwine, D. F.; Newton, R. S.; Sekerke, C. S.; Sliskovic, D. R.; Stratton, C. D.;
Wilson, M. W. J. Med. Chem. 1991, 34, 357e366.
10. Baumann, K. L.; Butler, D. E.; Deering, C. F.; Mennen, K. E.; Millar, A.; Nanninga,
T. N.; Palmer, C. W.; Roth, B. D. Tetrahedron Lett. 1992, 33, 2283e2284.
11. Oehrlein, R.; Baisch, G. Adv. Synth. Catal. 2003, 345, 713e715.
12. Radl, S. Synth. Commun. 2003, 33, 2275e2283.
A solution of acid 29 (52 mg, 0.08 mmol) and a catalytic amount
of camphor sulphonic acid in THF (2 mL) was stirred at room
temperature for 3 h. The mixture was concentrated and the residue
purified by flash chromatography (diethyl ether/methanol, 50:1) to
afford atorvastatin lactone 6 (38 mg, 90%) as white solid. It was
recrystallized from petroleum ether/ethyl acetate to give an
13. (a) Ghosh, A. K.; Lei, H. J. Org. Chem. 2000, 65, 4779e4781; (b) Tararov, V. I.;
Andrushko, N.; Andrushko, V.; Koenig, G.; Spannenberg, A.; Boerner, A. Eur. J.
Org. Chem. 2006, 5543e5550; (c) George, S.; Sudalai, A. Tetrahedron Lett. 2007,
48, 8544e8546.
amorphous white solid, mp 150e155 ꢀC {Ref. 30: 160e162 ꢀC}. Rf
20
(diethyl ether/methanol, 50:1) 0.25; [
a
]
þ25.5 (c 0.2, CHCl3)
D
23
{Ref. 9: [
a
]
þ24.53 (0.53% in CHCl3), Ref. 10: [
a]
þ26.05 (c 1,
D
D
€
14. For some reviews, see: (a) Muller, M. Angew. Chem. 2005, 117, 366e369; Angew.
CHCl3)}; dH (400 MHz, CDCl3) 1.50e1.53 (m, 6H, CH(CH3)2),
1.55e1.60 (m, 1H, lactone H-4), 1.65e1.77 (m, 2H, lactone H-4,
NCH2CH2), 1.82e1.91 (m, 1H, NCH2CH2), 2.37 (s, 1H, OH), 2.49e2.66
(m, 2H, lactone H-2), 3.48e3.58 (m, 1H, CH(CH3)2), 3.98e4.10 (m,
1H, NCH2), 4.16e4.29 (m, 2H, NCH2, lactone H-3), 4.44e4.54 (m, 1H,
lactone H-5), 6.87 (s, 1H, NH), 6.96e7.20 (m, 13H, aryl), 7.27e7.33
(m, 1H, aryl); dC (100 MHz, CD3OD) 21.7 (CH(CH3)2), 22.0 (CH
(CH3)2), 26.1 (CH(CH3)2), 35.6 (C-4, lactone), 37.0, 37.1 (NCH2CH2),
38.5 (C-2, lactone), 40.7 (NCH2), 62.4 (C-3, lactone), 73.0 (C-5, lac-
tone), 73.1, 115.6 (C-3, JC,F¼22.0 Hz, 4-FeC6H4), 115.6 (C-3, pyrrole),
119.7 (C-2, anilide), 122.1 (C-4, pyrrole), 123.6, 123.7 (C-4, anilide),
126.5, 126.6 (C-4, phenyl), 128.0 (C-1, JC,F¼2.9 Hz, 4-FeC6H4), 128.3,
128.4 (C-3, anilide), 128.4, 128.7 (C-2, anilide), 128.7 (C-5, pyrrole),
130.4 (C-3, phenyl), 131.3, 134.0, 133.1 (C-2, JC,F¼8.1 Hz, 4-FeC6H4),
134.4 (C-1, phenyl), 134.5, 138.2, 138.2 (C-1, anilide), 141.3 (C-2,
pyrrole), 162.3 (C-4, JC,F¼248.8 Hz, 4-FeC6H4), 164.9 (CONH), 169.4
(COO); HRMS (ESI) calcd for C33H33FN2O4 [MþNa]þ 563.23166,
found 563.23154.
Chem., Int. Ed. 2005, 44, 362e365; (b) Patel, J. M. J. Mol. Catal. B: Enzym. 2009, 61,
123e128; (c) Asako, H.; Shimizu, M.; Itoh, N. Appl. Microbiol. Biotechnol. 2009,
84, 397e405.
15. Bergeron, S.; Chaplin, D. A.; Edwards, J. H.; Ellis, B. S. W.; Hill, C. L.; Holt-Tiffin,
K.; Knight, J. R.; Mahoney, T.; Osborne, A. P.; Ruecroft, G. Org. Process Res. Dev.
2006, 10, 661e665.
16. Sun, F.; Xu, G.; Wu, J.; Yang, L. Tetrahedron: Asymmetry 2007, 18, 2454e2461.
17. (a) Liu, J.; Hsu, C.-C.; Wong, C.-H. Tetrahedron Lett. 2004, 45, 2439e2441; (b)
Greenberg, W. A.; Varvak, A.; Hanson, S. R.; Wong, K.; Huang, H.; Chen, P.; Burk,
M. J. Proc. Natl. Acad. Sci. U.S.A. 2004, 101, 5788e5793.
18. Beck, G.; Jendralla, H.; Kesseler, K. Synthesis 1995, 1014e1018.
19. Wess, G.; Kesseler, K.; Baader, E.; Bartmann, W.; Beck, G.; Bergmann, A.; Jen-
dralla, H.; Bock, K.; Holzstein, O.; Kleine, H.; Schnierer, M. Tetrahedron Lett. 1990,
31, 2545e2548.
20. See, for example: (a) Butler, D.E.; Le, T.V.; Nanninga, T.N. U.S. Patent 5,298,627
1994, 19 pp; CAN, 121, 57333. (b) Sattigeri, J.A.; Salman, M.; Rawat, S.; Sethi, S. In
PCT Int. Appl. (Ranbaxy Laboratories Limited, India). WO patent appl. 118536,
2005, 24 pp; CAN, 144, 51375.
21. Burns, N. Z.; Baran, P. S.; Hoffmann, R. W. Angew. Chem. 2009, 121, 2896e2910;
Angew. Chem., Int. Ed. 2009, 48, 2854e2867.
22. See, for example: (a) Schomaker, J. M.; Pulgam, V. R.; Borhan, B. J. Am. Chem.
Soc. 2004, 126, 13600e13601; (b) Heumann, L. V.; Keck, G. E. Org. Lett. 2007, 9,
1951e1954.
23. (a) Hassan, A.; Lu, Y.; Krische, M. J. Org. Lett. 2009, 11, 3112e3115; (b) Lu, Y.;
Krische, M. J. Org. Lett. 2009, 11, 3108e3111; Org. Lett. 2009, 11, 5362 (correc-
tion).
Acknowledgements
24. (a) Gololobov, Y. G.; Zhmurova, I. N.; Kasukhin, L. F. Tetrahedron 1981, 37,
437e472; (b) Tian, W. Q.; Wang, Y. A. J. Org. Chem. 2004, 69, 4299e4308.
25. For the bromination of related pyrrols, see: (a) Procopiou, P. A.; Draper, C. D.;
Hutson, J. L.; Inglis, G. G. A.; Ross, B. C.; Watson, N. S. J. Med. Chem. 1993, 36,
3658e3662; (b) Bratton, L. D.; Auerbach, B.; Choi, C.; Dillon, L.; Hanselman, J. C.;
Larsen, S. D.; Lu, G.; Olsen, K.; Pfefferkorn, J. A.; Robertson, A.; Sekerke, C.;
Trivedi, B. K.; Unangst, P. C. Bioorg. Med. Chem. 2007, 15, 5576e5589; (c) Garcia
Chapinal, F.; Asensio Dominguez, R.; Cruzado Rodriguez, M.C.; Herradon Garcia,
B.; Chicharro Martin, R. Span. Patent 2,289,945, 2008, 25 pp; CAN, 148, 561631.
Financial support by the Deutsche Forschungsgemeinschaft and
the Fonds der Chemischen Industrie is gratefully acknowledged. P.S.
acknowledges a fellowship from the Promotionsverbund ‘Identi-
fizierung und Validierung von Arzneistofftargets’ funded by the
€
€
Eberhard Karls Universitat Tubingen. We also thank the co-
ordinator, Prof. Oliver Werz, and members of the Promo-
tionsverbund for helpful discussions.
ꢀ
26. Coste, J.; Frerot, E.; Jouin, P.; Castro, B. Tetrahedron Lett. 1991, 32, 1967e1970; (b)
Coste, J.; Frerot, E.; Jouin, P. J. Org. Chem. 1994, 59, 2437e2446.
27. For a review about peptide bond formation, see: Han, S.-Y.; Kim, Y.-A. Tetra-
hedron 2004, 60, 2447e2467.
28. Hanessian, S.; Liak, T. J.; Vanasse, B. Synthesis 1981, 396e397.
29. Bal, B. S.; Childers, W. E.; Pinnick, H. W. Tetrahedron 1981, 37, 2091e2096.
30. Stach, J.; Havlicek, J.; Placek, L.; Radl, S. Collect. Czech. Chem. Commun. 2008, 73,
229e246.
Supplementary data
Supplementary data associated with this article (procedure for
alcohol 13, copies of NMR spectra) can be found in the online